Clinical Trial

A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the amount of LY3537031 that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants.
Protocol Amendment History 3 changes
critical Trial completed 2026-04-25
notable Primary completion pushed: 2026-03 -> 2026-04-16 2026-04-25
minor Completion pushed: 2026-03 -> 2026-04-16 2026-04-25
Trial Details
NCT Number NCT07165015
Lead Sponsor Eli Lilly and Company
Conditions Renal Impairment, Healthy, Renal Insufficiency, End Stage Renal Disease (ESRD)
Enrollment 31 participants
Start Date 2025-09-18
Primary Completion 2026-04-16 (estimated)
Study Completion 2026-04-16 (estimated)
Updated on ClinicalTrials.gov 2026-04-24